Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations: 2009-2024

Historic Cash from Operations for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$22.5 million.

  • Heron Therapeutics' Cash from Operations fell 60.52% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 263.96%. This contributed to the annual value of -$22.5 million for FY2024, which is 61.68% up from last year.
  • Per Heron Therapeutics' latest filing, its Cash from Operations stood at -$22.5 million for FY2024, which was up 61.68% from -$58.8 million recorded in FY2023.
  • Heron Therapeutics' Cash from Operations' 5-year high stood at -$22.5 million during FY2024, with a 5-year trough of -$203.4 million in FY2021.
  • In the last 3 years, Heron Therapeutics' Cash from Operations had a median value of -$58.8 million in 2023 and averaged -$76.1 million.
  • In the last 5 years, Heron Therapeutics' Cash from Operations tumbled by 48.35% in 2020 and then spiked by 61.68% in 2024.
  • Heron Therapeutics' Cash from Operations (Yearly) stood at -$184.8 million in 2020, then declined by 10.03% to -$203.4 million in 2021, then rose by 27.76% to -$146.9 million in 2022, then skyrocketed by 59.98% to -$58.8 million in 2023, then soared by 61.68% to -$22.5 million in 2024.